Skip to main content
SYRE
NASDAQ Life Sciences

Major Investor Fairmount Sells $400M in Spyre Therapeutics Stock; Director Resigns

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$86.5
Mkt Cap
$8.428B
52W Low
$14
52W High
$102.06
52W Position info
518% above low
Off High info
15% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $14 on elevated volume (2.1× avg).

Summary

Fairmount Healthcare Fund II L.P. sold approximately $400 million worth of Spyre Therapeutics common stock, significantly reducing its stake, following the resignation of its managing member, Peter Harwin, from the company's board.


Key Events · Ownership and Investor Activity · SYRE

  • Major Investor Divestment

    Fairmount Healthcare Fund II L.P. executed a block trade, selling 4,684,781 shares of common stock for approximately $400 million at $85.31 per share.

  • Director Departure

    Peter Harwin, a managing member of Fairmount, resigned from Spyre Therapeutics' Board of Directors on May 27, 2026, preceding the large stock sale.

  • Reduced Ownership Stake

    Following the sale and a preferred stock conversion, Fairmount's reported beneficial ownership in Spyre Therapeutics decreased to 9.15%.


Analysis · SYRE · Life Sciences

This filing reveals a substantial divestment by a major institutional investor, Fairmount Healthcare Fund II L.P., which sold approximately $400 million worth of stock. This significant sale, representing 4.74% of the company's market cap and nearly half of Fairmount's prior holdings, is a strong negative signal, especially as it follows the recent resignation of Peter Harwin, a managing member of Fairmount, from Spyre's board. This move by a key investor, despite recent positive clinical trial data and a successful capital raise, suggests a strategic reduction in their commitment to the company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYRE was trading at $86.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $14.00 to $102.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $104.50 info
Change: +$4.77 (+5%) info
Market Cap: $9.437B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $104.50 info
Change: +$4.77 (+5%) info
Market Cap: $9.437B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $104.50 info
Change: +$23.99 (+30%) info
Market Cap: $9.437B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $104.50 info
Change: +$24.39 (+30%) info
Market Cap: $9.437B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $104.50 info
Change: +$23.34 (+29%) info
Market Cap: $9.437B info